secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2023-06-12T23:59:59+00:00
Accession:  0001493152-23-020822
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran secures $500k equity investment from Triton Funds for COVID-19 trial funding
--------------------------------------------------------------------------------

- Triton Funds LP to purchase 1,612,903 shares at $0.31/share, totaling $500,000.
- Proceeds will fund dosage optimization study for mild-moderate COVID-19; dosing expected within month.
- Funding sufficient to reach Phase 3 regulatory submission milestone in India.
- Triton is second institutional investor alongside Walleye Capital (over $5B AUM).
- Company also amended WallachBeth engagement for brokerage of notes totaling $1.165M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315223020822/0001493152-23-020822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315223020822/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-020822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer